welcome robust to third has been and of We record and everyone Susan, delivered improving today's generation cash. XXXX sales, margin remarkable. Thank you, terms setting a gross in call. quarter of
you add people leading the to These would new worldwide environment, XXX,XXX last to third to welcome we chain with challenges than to continue and of any the people continue our navigate We the our be improve at And to impressive thank of members From quality further efforts manufacturing, clinical an base. year, our as everyone. COVID-XX. are contributing are and rate. lives sales we quarter more to the achievements team but to of installed especially mission in And since customers are of industry diabetes. so supply
portions at international worldwide Control-IQ, back the our quarter, and all takes between seasonality, created influencing the our slightly and domestic puts for internet sales demand patterns. Looking and vary These strong COVID-XX business. in of
demand the a the loudest time discussing making very teams impact field COVID-XX. in was we with country. our I detail. high some team with proud spend the interest byproduct our challenges opportunity remains adoption. sentiment supports clinical our more various of which community The that leading are navigation Control-IQ had are continued the our with of this still coupled the and I belief upfront members both from we technology. positive diabetes that in October, Demand the are was was and Their high, meet And in the our described I'll sales Control-IQ Starting with of innings of consistent. feedback So domestic regions largely on in market that of shared business, early to
sales of our territories nurse the and during educator. are typically have a both a we reminder, diabetes third As approximately rep And comprised territories a XX quarter.
team's we when training grown anticipation and and the has productivity of and XX to we thin is this months, to clinical growth work was past stretched a sales began were in-person With available process continuing environment. operating remote rate very in began lift in with of our territory in the sales increasing. high, in calls capacity their COVID manageable Over That which beyond, as The became of are XXX we to XXXX mind, up expanding approximately in territories. keep demand. restrictions
training investing that sales internal We teams also the are our processes. in support and customer
healthcare shortages by discussed broader dynamic experienced is are labor interesting also Another teams the being the field impacting that prescriber country across our offices.
to source use their have workload, our remotely is some prominent or our the in see in to patients sphere out are to the Tandem This provider are back in why so handle healthcare And staff data The data of it's new to the and patient therapy platform initiatives accommodate enhance days important. platforms and generation and result, provider a engagement build whether place of office patient t:connect designed continued management represents with data telemedicine. application. facing As the we fewer office providers having that office.
fewer typically deliver to Beginning continuing COVID-XX of ordering more as is off also third our Then we to in the referrals, time different Even we quarter. update, the shift are step U.S. holiday interactions. some October, process. COVID-XX support by impact which Internationally, in for we And prescribing saw pump in greatly the European invest seasonality of concentrated on variants COVID-XX management, alike. software experienced to people territories the the we based related again order in saw in varies during We was to patient quarter, increase in value saw and took at the to the efficiency also period in for this began Overall, a users what cloud to these office well-deserved which less the notable activities added of to anticipated we the even traditional similar that Europe, first summer once providers in by seasonality see order and office, streamline prescriber later geography. to in tools more increase healthcare fluctuations. rates was live diagnosis season. beginning the with a quarter, sales to pump and begin
outside to to with While United people are which be most the States, systems pressured diabetes being continues COVID. hospital by the seen
Our really the in, the our XX, can be the positive technology. recently, are and to underpenetrated outperformance and to overwhelmingly more large markets t:slim Control-IQ nature we that response of attributed
additional hear we in Our domestically. technology, stages France that in opportunity. is enthusiasm very are experiences particularly outside we encouraging our doing States, are significant their Control-IQ experience which Germany, early great about distribution This identify less to positive people's Control-IQ the the launch a are and partners job with by are in the The that hearing United still as with prescribers about the mirror sales of COVID-XX. market efforts impacted we provides
we are expect launch take steps build number a there in to beyond. the product XXXX that As over a and countries next bringing to throughout months in the of XX and benefit place these provide market,
our efforts As the markets. focus penetration that U.S. plan drives of is Control-IQ supporting on In distribution technology we've demonstrating XXXX, of international domestically, partners burden our we It diabetes. seen their when in launch to deeper to our international reduces customer adoption. drive
supply activities, doing the In teams related addition COVID-XX. navigating our and outstanding are an chain internal manufacturing and pressures our job to also to quality sales clinical
look manage activities our management capacity semiconductor XXXX from keep as take we isolated contact close to and suppliers. beyond, manufacturing and continue to evaluating we perspective, are From ahead sourcing and lines in regularly carefully and accordingly. expanding needs will adding a is with our of no the supply pride issues we costs, constraints. in increasing While throughout supply great more success pandemic. the our like We And shipping chain one the global overall and
we to times labor proud and capacity oriented Moving and perform a during as we of majority a markets. was the of party am various team's approach how XXXX our also headwinds perspective. to to on cartridge the from continue challenging cost these it But I in manufacturer are rely the proved different provided be it from beneficial manufacturing overcoming to a solution very able to Overall, third was more pandemic. fortuitous
can you associated some experienced the though have the even COVID changes with to As see, environment. domestic unusual we seasonality
being positioned expanding and and real ISPAD EASD traditional also be and individuals worldwide overwhelmingly deliver leading Incredibly, term with has can these ongoing world Control-IQ, as in We This reflects the combined technology, two-thirds candidates our with historically. to that market shared Control-IQ pump experiences most at just our technology, near conferences both all now Control-IQ from are the XX The presented customers the demonstrating more data on to including reported with data the by footprint customers thought clinical positive. meetings. XXX,XXX longer our at our us using not global t:slim of continues data Type diabetes the recently benefit well are how of than Control-IQ, highlights growth. X presented
in we the encouraging There lowering pediatric and adverse events data did highlighted to higher who in with reduction as individuals a as have had well not two access technology that those from on above. AXc indication was For prepare and example, particularly Control-IQ to to very hemoglobin which in pursue also down its as presented significant users, Control-IQ. six, young users past ages age is
regulatory a recall, data to support evaluate population. in use submission intend And to of of study you'll the we As a supporting we XXXX. the multi-site use Control-IQ to this are age the by end pediatric
be also Type living expanded people diabetes. for labeling an pursuing will We X indication with
enrollment conduct that color pivotal is this month, schedule Our our Type inform set feature feasibility provide to plan then on we later to we start year. plan clinical expanded got next study We've Control-IQ for our will in first trial with to this on also year. will X and that trial an additional
has to this our active can FDA for see, been with upcoming and efforts, you very for responsive we've requests been quarter. our As the approving clinical studies IDEs
Dexcom's dependencies of in with as also GX a advance submission, clearances. regulatory that we to of bolus year-ago. launch. continued the XX-K FDA initiatives to questions we Libre other submitted a to continuing team R&D partners either different have pump, work Abbott's these prepare all t:sport XX in to with for the is bolus of t:sport the CGM sensor, as feature for Each August integration XXXX, that and our own of mobile File the or for providing at timeline FDA as responded as by our Three continuing late secure for the technology our the key progress. obtain FDA our t:slim look well and to review are about clearance We also mobile our Our they
own is this development at continue XXXX. looking our work able time. And to unimpeded However, beyond
is than more take we been we pipeline call internally, strategy innovation longer-term vision can like over product on time visibility the to years. into. like haven't our We'd to growth attention driving today's. putting to is which our for a five something increasing expansive much on a you, given with But share we've next cover investors Our the
X. Participation join which invite and focused you be will over event, to XXXX And we and time. place turn portion So at center Leigh. in and our on on sharing meantime, the registration to more December can our day are details Investor you that, the R&D setting strategy of another forward an be call the us successful Monday, With In we on take now a look virtually found strong website. with we on year. finish point up to vision XXXX I'll that to to for
